Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is not recommended during pregnancy. Clinical guidance is clear on this point: the medicine has not been adequately studied in pregnant people, and animal studies have shown potential risks to the developing foetus. If you are pregnant, think you might be, or are planning a pregnancy, tirzepatide should be stopped and a prescriber or GP consulted promptly. These are prescription-only medicines, and any decision about stopping, switching or continuing treatment belongs with a qualified clinician who knows your full history. You can read more about how Mounjaro works and who it is licensed for on our main treatment page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a situation that can feel alarming, and it is more common than many people expect, partly because tirzepatide slows gastric emptying and may reduce absorption of the oral contraceptive pill in the first weeks of treatment or after a dose increase. The practical consequence is that some women have an unplanned pregnancy while on the medicine, and if you are wondering whether you can use Mounjaro when pregnant, the short answer is that it is not recommended.
The first step is straightforward: stop the injections. Do not wait for your next scheduled dose, and do not wait to speak to the pharmacist who supplies the medicine. Contact your GP or midwife the same day or the next morning, before the 12pm cut-off if you want a same-day call-back. They need to know you have been on tirzepatide so they can flag it in your notes and monitor accordingly.
The NHS guidance on weight-management injections notes that Mounjaro is not recommended in pregnancy, and the Mounjaro Summary of Product Characteristics published on the electronic Medicines Compendium advises discontinuation. Animal reproduction studies showed adverse effects at exposures relevant to therapeutic doses, which is the primary basis for the caution. Human data are too limited to draw firm conclusions in either direction, which is precisely why the conservative position is to stop.
Stopping will not undo any exposure that has already occurred, but continuing adds further exposure that has no clinical justification when safer alternatives exist for managing weight or blood sugar during pregnancy. Our page covering Mounjaro and pregnancy sets out what the current evidence says and what your midwifery team and obstetrician can guide you through for next steps.
If you are planning to conceive rather than already pregnant, the picture is a little different because you have time to plan. Both the MHRA and NHS England's guidance on weight-management injections advise that women intending to become pregnant should stop the medicine and allow a wash-out period before trying.
The specific length of that window is a prescriber conversation, not a fixed public rule, because it depends on your dose, how long you have been on treatment, and your individual circumstances. What we can say is that tirzepatide has a half-life of approximately five days, so it clears the body over a matter of weeks rather than months, unlike some medicines that require a prolonged gap. Your GP or fertility specialist is the right person to give you a personalised timeline.
It is also worth thinking about what happens to weight after stopping. Many people find that appetite returns and some of the weight lost during treatment gradually comes back. That is not a reason to continue the medicine into pregnancy, but it is a reason to have an honest conversation with your doctor about managing your health during the conception period and beyond. Weight management in pregnancy is a specialist area; the right support is from your maternity team.
Our detailed page on taking Mounjaro when pregnant covers the wash-out discussion in more depth for those who are planning ahead.
This sits at the centre of why unplanned pregnancies can occur on tirzepatide. Mounjaro slows gastric emptying, which affects how quickly the stomach passes its contents into the small intestine. For most medicines this is a minor consideration. For the oral contraceptive pill, whose absorption depends on gut transit, it can meaningfully reduce effectiveness.
NHS guidance, reflected on the NHS Inform Scotland page on weight-loss medication, recommends that women on the pill add a non-oral method of contraception for the first four weeks of starting Mounjaro and for four weeks after each dose increase. A barrier method such as condoms is the practical answer for most people. This is not a reason to avoid Mounjaro; it is a reason to be informed before you start.
If you use a non-oral hormonal method (patch, ring, implant, injection or coil), this interaction does not apply. If you are unsure which category your contraception falls into, your GP or pharmacist can clarify in a quick conversation. Anyone who has questions about whether they can have Mounjaro when pregnant after a contraception concern is entitled to an early pregnancy test and a frank discussion with a clinician.
For broader questions about the medicine's suitability for you, our free consultation service connects you with a GPhC-registered prescriber who can review your circumstances the same day.
Mounjaro is not recommended during breastfeeding either. It is not known whether tirzepatide passes into breast milk in meaningful amounts, but given the absence of safety data and the potential for harm, clinical guidance is to avoid it while breastfeeding. If you want to restart treatment after delivery, discuss timing with your GP, particularly if you are breastfeeding.
For those who are actively trying to conceive, questions about whether you can take Mounjaro when pregnant are worth exploring with your GP before trying, because conception can happen before a positive test and the weeks immediately after fertilisation are biologically significant. Stopping the medicine before trying to conceive, rather than waiting to confirm a pregnancy, is the approach consistent with NHS guidance.
There is currently no evidence that previous use of Mounjaro affects fertility. Studies have not shown a causal link between tirzepatide and impaired fertility, and for many people with obesity, weight loss itself is associated with improved fertility outcomes. These are nuanced points worth discussing with a fertility specialist or your GP, not something to self-navigate. Our clinical team can signpost you appropriately during any consultation, and our frequently asked questions cover several related situations. If you have specific concerns, our support team is available seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.